RESEARKA

The evidence base for safety and comorbidity outcomes associated with renin-angiotensin system modulation encompasses diverse study designs and patient populations. Observational cohort studies, including the DAPA-SRV trial, evaluated dapagliflozin in adults with systemic right ventricular dysfunction (Albertini 2025). The DIGIT-HHF trial characterized baseline characteristics of patients with advanced chronic heart failure in a randomized, double-blind, placebo-controlled design (Bavendiek 2025). Real-world analyses examined sacubitril/valsartan effectiveness in dialysis patients with heart failure with reduced ejection fraction, reporting on hospitalization and mortality endpoints (Tu 2026). Systematic reviews synthesized evidence on sacubitril/valsartan's impact on sleep-disordered breathing in chronic heart failure patients (Kuang 2025) and its efficacy in peritoneal dialysis populations (Silva 2026). Pharmacovigilance analyses based on the FDA Adverse Event Reporting System assessed renal failure risk (Wang 2025), while prospective protocols investigated ARBs in oncology contexts (Wang 2025c).

Citation Support

• source_1 Solomon 2026
• source_2 Din 2026
• source_3 Li 2025
• source_4 Mei 2025
• source_5 Chung 2024